As of Nov 19, 2026, 1 of 1 active firms rate PAVM a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PAVM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.60
Range $-0.60 – $-0.60 · 1 analysts · -49% YoY
Next period, 1 analysts expect PAVmed Inc to earn $-0.60 a share (range $-0.60 – $-0.60), versus $-1.17 a year earlier. Full-year consensus is $-2.33, growing to $-2.38 the year after.
REVENUE · NEXT QUARTER
$87.5K
Range $75.0K – $100.0K · 1 analysts · +298% YoY
Revenue is expected to reach $87.5K (range $75.0K – $100.0K), +297.7% year-over-year. Full-year consensus is $232.5K, rising to $600.0K next year.
Top analysts covering PAVmed Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PAVM.
#1
Anthony Vendetti
Maxim Group · Rank #456
Buy
$16.00+1130.8% to target
Overall win rate
28%
+ Follow
#2
Edward Woo
Ascendiant Capital · Rank #570
Buy
$57.00+4284.6% to target
Overall win rate
24%
+ Follow
PAVM stock forecast FAQ
What is PAVM's average 12-month price target?+
The 1 active firms with a live target average $57.00 for PAVmed Inc over the next 12 months, ranging from a $57.00 high to a $57.00 low, as of Nov 19, 2026.
Is PAVM stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover PAVM?+
1 active firms have a recognized rating on PAVmed Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PAVM?+
Among analysts who currently cover PAVM, Anthony Vendetti of Maxim Group has the strongest overall Quantellect track record (Rank #456). Their current call is Buy with a $16.00 target.
What is PAVmed Inc's projected EPS for next quarter?+
The consensus estimate is $-0.60 per share (range $-0.60 – $-0.60) across 1 analysts. Full-year EPS is projected at $-2.33, rising to $-2.38 the following year.
How much revenue is PAVmed Inc expected to report next quarter?+
Consensus revenue is $87.5K (range $75.0K – $100.0K). Full-year revenue is projected at $232.5K, growing to $600.0K next year.
Have analysts been upgrading or downgrading PAVM lately?+
As of Nov 19, 2026, 1 of 1 active firms rate PAVM a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PAVM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.